# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K082162   
B. Purpose for Submission: Clearance of new device   
C. Measurand: Erythrocytes, Monocytes, Lymphocytes   
D. Type of Test: Quality Control Material   
E. Applicant: Beckman-Coulter INC   
F. Proprietary and Established Names: Coulter Body Fluid Control

# G. Regulatory Information:

1. Regulation section:   
21 CFR 864.8625

2. Classification: Class II

3. Product code: JPK

4. Panel: 81 Hematology

# H. Intended Use:

1. Intended use(s):

The Beckman-Coulter Body Fluid Control is a hematology quality control material used to monitor the performance and verify the measuring range of the body fluid cycle of the UniCel $\textsuperscript { \textregistered }$ DxH 800 COULTER Cellular Analysis System.

2. Indication(s) for use:

3. Special conditions for use statement(s):

4. Special instrument requirements:

UniCel $\textsuperscript { \textregistered }$ DxH 800 COULTER Cellular Analysis System (K081930)

# I. Device Description:

The Beckman-Coulter Body Fluid Control is a hematology quality control mixture intended to be used with the UniCel $\textsuperscript { \textregistered }$ DxH 800 COULTER Cellular Analysis System (K081930). It consists of 3 levels of treated, stabilized human erythrocytes, a stabilized platelet-sized component, and fixed erythrocytes that simulate leukocytes. The platelet-sized components are not assayed nor reported in the body fluid cycle.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

COULTER $\textsuperscript { \textregistered }$ 5C $\textsuperscript { \textregistered }$ Cell Control (cleared as COULTER $\textsuperscript { \textregistered }$ PX Cell Control)

2. Predicate 510(k) number(s): K912133, K060464

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quality control materialintended to monitor theperformance of ahematology analyzer</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Product composition</td><td rowspan=1 colspan=1>Treated, stabilized humanerythrocytes in anisotonic medium, andstabilized platelet-sizedcomponent, and fixederythrocytes to simulateleukocytes</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>3 levels</td><td rowspan=1 colspan=1>same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Cellular Population</td><td rowspan=1 colspan=1>Erythrocytes, Platelets,Lymphocytes, andmonocytes</td><td rowspan=1 colspan=1>Erythrocytes, platelets,lymphocytes, monocytes,neutrophils, andeosinophils</td></tr><tr><td rowspan=1 colspan=1>Assayed Parameters</td><td rowspan=1 colspan=1>RBC and TNC</td><td rowspan=1 colspan=1>WBC, RBC, HGB, HCT,MCV, MCH, MCHC,RDW, RDW-SD, PLT,MPV, Ly%, Mo%, Ne%,Eo%, Ba%, Ly#, Mo#,Ne#, Eo#, Ba#</td></tr><tr><td rowspan=1 colspan=1>Analyzers</td><td rowspan=1 colspan=1>UniCel® DxH 800</td><td rowspan=1 colspan=1>COULTER® LH 780,LH 750, GENS*S,STKS, LH 500, HmX,HmX w. Autoloader,MAXM, &amp; MAXM w.Autoloader</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

L. Test Principle:

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Body Fluids Level 1

<table><tr><td rowspan=1 colspan=3>% CV</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>TNC</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>Lot 3</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>9.2</td></tr></table>

Body Fluids Level 2

<table><tr><td rowspan=1 colspan=3>% CV</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>TNC</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Lot 3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td></tr></table>

Body Fluids Level 3

<table><tr><td rowspan=1 colspan=3>% CV</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>TNC</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Lot 3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.1</td></tr></table>

b. Linearity/assay reportable range: N/A   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): The product was evaluated for real-time open and closed vial stability. d. Detection limit: N/A   
e. Analytical specificity: N/A   
f. Assay cut-off: N/A

2. Comparison studies:

a. Method comparison with predicate device: N/A

b. Matrix comparison: N/A

3. Clinical studies:

a. Clinical Sensitivity: N/A

b. Clinical specificity: N/A

c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off: N/A

5. Expected values/Reference range: N/A

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.